Literature DB >> 28853896

The Weak Link: Optimization of the Ligand-Nanoparticle Interface To Enhance Cancer Cell Targeting by Polymer Micelles.

Jing Wang1, Michael Dzuricky1, Ashutosh Chilkoti1.   

Abstract

Many promising targeting ligands are hydrophobic peptides, and these ligands often show limited accessibility to receptors, resulting in suboptimal targeting. A systematic study to elucidate the rules for the design of linkers that optimize their presentation on nanoparticles has not been carried out to date. In this study, we recombinantly synthesized an elastin-like polypeptide diblock copolymer (ELPBC) that self-assembles into monodisperse micelles. AHNP and EC1, two hydrophobic ErbB2-targeted peptide ligands, were incorporated at the C-terminus of the ELPBC with an intervening peptide linker. We tested more than 20 designs of peptide linkers, where the linker could be precisely engineered at the gene level to systematically investigate the molecular parameters-sequence, length, and charge-of the peptide linker that optimally assist ligands in targeting the ErbB2 receptor on cancer cells. We found that peptide linkers with a minimal length of 12 hydrophilic amino acids and an overall cationic charge-and that impart a zeta potential of the micelle that is close to neutral-were necessary to enhance the uptake of peptide-modified ELPBC micelles by cancer cells that overexpress the ErbB2 receptor. This work advances our understanding of the optimal presentation of hydrophobic ligands by nanoparticles and suggests design rules for peptide linkers for targeted delivery by polymer micelles, an emerging class of nanoparticle carriers for drugs and imaging agents.

Entities:  

Keywords:  ErbB2; Linker optimization; affinity targeting; elastin-like polypeptide; hydrophobic ligand; nanoparticle

Mesh:

Substances:

Year:  2017        PMID: 28853896      PMCID: PMC6372105          DOI: 10.1021/acs.nanolett.7b02225

Source DB:  PubMed          Journal:  Nano Lett        ISSN: 1530-6984            Impact factor:   11.189


  46 in total

1.  Purification of recombinant proteins by fusion with thermally-responsive polypeptides.

Authors:  D E Meyer; A Chilkoti
Journal:  Nat Biotechnol       Date:  1999-11       Impact factor: 54.908

2.  Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis.

Authors:  A Berezov; H T Zhang; M I Greene; R Murali
Journal:  J Med Chem       Date:  2001-08-02       Impact factor: 7.446

Review 3.  Designing peptide receptor agonists and antagonists.

Authors:  Victor J Hruby
Journal:  Nat Rev Drug Discov       Date:  2002-11       Impact factor: 84.694

4.  Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo.

Authors:  B W Park; H T Zhang; C Wu; A Berezov; X Zhang; R Dua; Q Wang; G Kao; D M O'Rourke; M I Greene; R Murali
Journal:  Nat Biotechnol       Date:  2000-02       Impact factor: 54.908

Review 5.  Monoclonal antibody therapy of cancer.

Authors:  Gregory P Adams; Louis M Weiner
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

Review 6.  Overexpression of ErbB2 in cancer and ErbB2-targeting strategies.

Authors:  D Yu; M C Hung
Journal:  Oncogene       Date:  2000-12-11       Impact factor: 9.867

Review 7.  Peptide and protein drug delivery to and into tumors: challenges and solutions.

Authors:  Vladimir P Torchilin; Anatoly N Lukyanov
Journal:  Drug Discov Today       Date:  2003-03-15       Impact factor: 7.851

8.  AHNP-streptavidin: a tetrameric bacterially produced antibody surrogate fusion protein against p185her2/neu.

Authors:  K Masuda; M Richter; X Song; A Berezov; K Masuda; R Murali; M I Greene; H Zhang
Journal:  Oncogene       Date:  2006-06-19       Impact factor: 9.867

9.  Block copolymer micelles for drug delivery: design, characterization and biological significance.

Authors:  K Kataoka; A Harada; Y Nagasaki
Journal:  Adv Drug Deliv Rev       Date:  2001-03-23       Impact factor: 15.470

10.  Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells.

Authors:  Stephanie C Pero; Girja S Shukla; Amy L Armstrong; Daniel Peterson; Susan P Fuller; Katherine Godin; Sarah L Kingsley-Richards; Donald L Weaver; Jeffrey Bond; David N Krag
Journal:  Int J Cancer       Date:  2004-10-10       Impact factor: 7.396

View more
  3 in total

1.  Active Targeting of Cancer Cells by Nanobody Decorated Polypeptide Micelle with Bio-orthogonally Conjugated Drug.

Authors:  Simone A Costa; Davoud Mozhdehi; Michael J Dzuricky; Farren J Isaacs; Eric M Brustad; Ashutosh Chilkoti
Journal:  Nano Lett       Date:  2018-12-14       Impact factor: 11.189

2.  Concentration-Independent Multivalent Targeting of Cancer Cells by Genetically Encoded Core-Crosslinked Elastin/Resilin-like Polypeptide Micelles.

Authors:  Patrick Weber; Michael Dzuricky; Junseon Min; Irene Jenkins; Ashutosh Chilkoti
Journal:  Biomacromolecules       Date:  2021-09-03       Impact factor: 6.978

3.  Leutusome: A Biomimetic Nanoplatform Integrating Plasma Membrane Components of Leukocytes and Tumor Cells for Remarkably Enhanced Solid Tumor Homing.

Authors:  Hongliang He; Chunqing Guo; Jing Wang; William J Korzun; Xiang-Yang Wang; Shobha Ghosh; Hu Yang
Journal:  Nano Lett       Date:  2018-09-17       Impact factor: 11.189

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.